David Mountcastle Sells 2,320 Shares of Privia Health Group, Inc. (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 2,320 shares of Privia Health Group stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total value of $42,734.40. Following the completion of the sale, the chief financial officer now directly owns 259,959 shares in the company, valued at approximately $4,788,444.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

David Mountcastle also recently made the following trade(s):

• On Tuesday, April 2nd, David Mountcastle sold 3,933 shares of Privia Health Group stock. The shares were sold at an average price of $17.77, for a total transaction of $69,889.41.

Privia Health Group Stock Up 1.8 %

Shares of Privia Health Group stock opened at $18.74 on Friday. Privia Health Group, Inc. has a 52 week low of $17.54 and a 52 week high of $30.15. The company has a market capitalization of $2.22 billion, a PE ratio of 98.64, a price-to-earnings-growth ratio of 2.52 and a beta of 0.81. The stock’s fifty day moving average is $19.64 and its two-hundred day moving average is $21.14.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The company had revenue of $440.80 million during the quarter, compared to the consensus estimate of $425.81 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. As a group, research analysts anticipate that Privia Health Group, Inc. will post 0.26 earnings per share for the current year.

Hedge Funds Weigh In On Privia Health Group

A number of institutional investors have recently modified their holdings of the stock. Advisors Preferred LLC purchased a new stake in shares of Privia Health Group in the fourth quarter valued at approximately $2,137,000. Loomis Sayles & Co. L P lifted its holdings in shares of Privia Health Group by 1.2% in the 3rd quarter. Loomis Sayles & Co. L P now owns 623,870 shares of the company’s stock worth $14,349,000 after buying an additional 7,577 shares during the period. Walleye Capital LLC bought a new position in shares of Privia Health Group during the 3rd quarter worth $1,394,000. Riverbridge Partners LLC increased its stake in shares of Privia Health Group by 8.7% during the fourth quarter. Riverbridge Partners LLC now owns 4,342,385 shares of the company’s stock valued at $100,005,000 after buying an additional 348,852 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Privia Health Group by 0.5% in the third quarter. Vanguard Group Inc. now owns 11,003,989 shares of the company’s stock valued at $253,092,000 after acquiring an additional 51,317 shares in the last quarter. 94.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PRVA. TD Cowen dropped their price objective on shares of Privia Health Group from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Barclays started coverage on Privia Health Group in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $22.00 price target for the company. Jefferies Financial Group began coverage on Privia Health Group in a research report on Monday, February 26th. They set a “buy” rating and a $25.00 price objective on the stock. Canaccord Genuity Group dropped their target price on Privia Health Group from $41.00 to $37.00 and set a “buy” rating for the company in a report on Tuesday, March 19th. Finally, JPMorgan Chase & Co. decreased their price target on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 6th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Privia Health Group has a consensus rating of “Moderate Buy” and a consensus price target of $27.62.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.